ArticleMolecular and clinical oncology2013
The biology of uterine sarcomas: A review and update.
Article in Molecular and clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 75 citations in OpenAlex.
- Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.Gynecologic oncology · 2016Trial
- A Rare Case of Endometrial Adenosarcoma and Its Management: A Case Report and Literature Review.Cureus · 2025Article
- CouldBiomedicines · 2025Article
- Preoperative identification from occult leiomyosarcomas in laparoscopic hysterectomy and laparoscopic myomectomy: accuracy of the ultrasound scoring system (PRESS-US).La Radiologia medica · 2024Article
- Current Treatment Options: Uterine Sarcoma.Current treatment options in oncology · 2024Review
- Exploring the Clinicopathological Diversity in Sarcomatous Transformations in the Uterus.Cureus · 2024Article
- The role of extracellular vesicles in the pathogenesis of gynecological cancer.Frontiers in oncology · 2024Review
- Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Comprehensive Multidisciplinary Update.Medicina (Kaunas, Lithuania) · 2023Review
- Epigenetic Features in Uterine Leiomyosarcoma and Endometrial Stromal Sarcomas: An Overview of the Literature.Biomedicines · 2022Review
- Comparative whole transcriptome analysis of gene expression in three canine soft tissue sarcoma types.PloS one · 2022Article
- DPP6 and MFAP5 are associated with immune infiltration as diagnostic biomarkers in distinguishing uterine leiomyosarcoma from leiomyoma.Frontiers in oncology · 2022Article
- Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies.Frontiers in pharmacology · 2022Review
- Uterine carcinosarcoma with extensive extrauterine component.BMJ case reports · 2021Article
- Leiomyosarcoma of the Uterus: A Rare Diagnosis.Cureus · 2021Article
- Identification of uterine leiomyosarcoma-associated hub genes and immune cell infiltration pattern using weighted co-expression network analysis and CIBERSORT algorithm.World journal of surgical oncology · 2021Article
- Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview.International journal of molecular sciences · 2021Review
- The mutational repertoire of uterine sarcomas and carcinosarcomas in a Brazilian cohort: A preliminary study.Clinics (Sao Paulo, Brazil) · 2021Article
- [Interdisciplinary S2k guidelines on the diagnosis and treatment of uterine sarcomas-recommendations for surgical pathology].Der Pathologe · 2020Review
- [Expressions of HELQ and RAD51C in endometrial stromal sarcoma and their clinical significance].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine sarcoma is a rare neoplasm, accounting for only 5% of uterine malignancies. The pathogenesis of uterine sarcoma remains largely unknown, although recent basic science and pre-clinical animal models have provided a better understanding of tumor biology. The aim of this study was to review the clinical features, imaging characteristics, genetic aberrations and therapeutic approaches in uterine sarcoma. This study reviewed the English-language literature on clinical and basic studies on uterine sarcoma. The common variants of uterine sarcoma are carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma (ESS). Genetic profiling efforts have identified amplification, overexpression and mutation, while the molecular mechanisms of tumorigenesis driven by these genomic and genetic aberrations have yet to be fully elucidated yet. Recent genome-wide studies have also identified complex chromosomal rearrangements as oncogenic mechanisms. The cell cycle regulators, p16 and p53, are frequently over-expressed and appear to be involved in key modifications of sarcomagenesis. Molecular-targeted therapy has now been evaluated in clinical trials for certain subtypes. In conclusion, aberrations of cell cycle control would be a critical step in the development of uterine sarcoma. This review has provided new areas of study targeting molecular and genetic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.